|
US7060708B2
(en)
*
|
1999-03-10 |
2006-06-13 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
|
US6716452B1
(en)
*
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
|
US8394813B2
(en)
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
|
US20070066537A1
(en)
*
|
2002-02-22 |
2007-03-22 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
|
US7375082B2
(en)
*
|
2002-02-22 |
2008-05-20 |
Shire Llc |
Abuse-resistant hydrocodone compounds
|
|
US7338939B2
(en)
*
|
2003-09-30 |
2008-03-04 |
New River Pharmaceuticals Inc. |
Abuse-resistant hydrocodone compounds
|
|
US7169752B2
(en)
*
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
|
AU2003219863C1
(en)
*
|
2002-02-22 |
2009-03-05 |
Shire Llc |
Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
|
|
US7105486B2
(en)
*
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
|
US7700561B2
(en)
*
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
|
US7659253B2
(en)
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
|
WO2003072735A2
(en)
*
|
2002-02-22 |
2003-09-04 |
New River Pharmaceuticals Inc. |
Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
|
|
GB0218811D0
(en)
*
|
2002-08-14 |
2002-09-18 |
Cenes Ltd |
Salts of morphine-6-glucuronide
|
|
US8133881B2
(en)
|
2003-01-13 |
2012-03-13 |
Shire Llc |
Carbohydrate conjugates to prevent abuse of controlled substances
|
|
JP4898445B2
(ja)
|
2003-05-29 |
2012-03-14 |
シャイア エルエルシー |
乱用抵抗性アンフェタミン化合物類
|
|
EA008864B1
(ru)
*
|
2003-09-30 |
2007-08-31 |
Нью Ривер Фармасьютикалз Инк. |
Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
|
|
CN101426481B
(zh)
*
|
2006-04-21 |
2012-12-05 |
帝斯曼知识产权资产管理有限公司 |
阿片受体拮抗剂的用途
|
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
|
FR2939436B1
(fr)
*
|
2008-12-10 |
2010-12-17 |
Sanofi Aventis |
Synthese de morphine-6-glucuronide ou de l'un de ses derives
|
|
EP2552433A4
(en)
|
2010-03-30 |
2013-11-06 |
Algynomics Inc |
COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
|
|
US8716350B2
(en)
*
|
2010-03-30 |
2014-05-06 |
Algynomics Inc. |
Compositions and methods for the treatment of somatosensory disorders
|
|
ME02367B
(me)
|
2010-09-21 |
2016-06-20 |
Purdue Pharma Lp |
Analozi buprenorfina kao agonisti i/ili antagonisti opioidnog receptora
|
|
IN2014DN03009A
(enExample)
|
2011-10-26 |
2015-05-08 |
Kempharm Inc |
|
|
US10138207B2
(en)
|
2012-11-09 |
2018-11-27 |
Purdue Pharma, L.P. |
Benzomorphan analogs and the use thereof
|
|
TW201434842A
(zh)
|
2012-12-07 |
2014-09-16 |
Purdue Pharma Lp |
丁基原啡因（ｂｕｐｒｅｎｏｒｐｈｉｎｅ）類似物類
|
|
ES2631197T3
(es)
|
2012-12-14 |
2017-08-29 |
Purdue Pharma Lp |
Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes
|
|
EP2931726B1
(en)
|
2012-12-14 |
2017-01-25 |
Purdue Pharma LP |
Spirocyclic morphinans and their use
|
|
EP2951160B1
(en)
|
2013-01-31 |
2019-04-24 |
Purdue Pharma LP |
Benzomorphan analogs and the use thereof
|
|
US8969358B2
(en)
|
2013-03-15 |
2015-03-03 |
Purdue Pharma L.P. |
Buprenorphine analogs
|
|
HU231191B1
(hu)
|
2013-04-15 |
2021-08-30 |
Szegedi Tudományegyetem |
Izotóp tartalmú morfin molekulák
|
|
WO2015097547A1
(en)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
10-substituted morphinan hydantoins
|
|
EP3087057A4
(en)
|
2013-12-26 |
2017-06-28 |
Purdue Pharma LP |
Ring-contracted morphinans and the use thereof
|
|
EP3087078B1
(en)
|
2013-12-26 |
2019-05-15 |
Purdue Pharma LP |
7-beta-alkyl analogs of orvinols
|
|
US9862726B2
(en)
|
2013-12-26 |
2018-01-09 |
Purdue Pharma L.P. |
Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
|
|
WO2015097546A1
(en)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
Propellane-based compounds and their use as opioid receptor modulators
|
|
EP3086790A4
(en)
|
2013-12-27 |
2017-07-19 |
Purdue Pharma LP |
6-substituted and 7-substituted morphinan analogs and the use thereof
|
|
CA2950567A1
(en)
|
2014-05-27 |
2015-12-03 |
Purdue Pharma L.P. |
Spirocyclic morphinans and use thereof
|
|
CA2951697A1
(en)
|
2014-06-13 |
2015-12-17 |
Purdue Pharma L.P. |
Azamophinan derivatives and use thereof
|
|
CA2969221C
(en)
|
2014-12-02 |
2021-01-12 |
Travis Mickle |
Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof
|
|
MA41125A
(fr)
|
2014-12-05 |
2017-10-10 |
Purdue Pharma Lp |
Dérivés de 6.7-cyclomorphinane et leur utilisation
|
|
ITUB20154996A1
(it)
|
2015-10-27 |
2017-04-27 |
Nobili S P A |
Attrezzatura per l?erogazione di un liquido di trattamento ad una rispettiva coltura o piantagione agricola.
|
|
WO2018023017A1
(en)
|
2016-07-29 |
2018-02-01 |
Janssen Pharmaceutica Nv |
Methods of treating prostate cancer
|
|
US10745402B2
(en)
|
2017-01-02 |
2020-08-18 |
Purdue Pharma L.P. |
Morphinan derivatives and use thereof
|
|
US10807995B2
(en)
|
2018-07-13 |
2020-10-20 |
Alkermes Pharma Ireland Limited |
Thienothiophene compounds for long-acting injectable compositions and related methods
|
|
US10799496B2
(en)
|
2018-07-13 |
2020-10-13 |
Alkermes Pharma Ireland Limited |
Naphthylenyl compounds for long-acting injectable compositions and related methods
|
|
US10975099B2
(en)
|
2018-11-05 |
2021-04-13 |
Alkermes Pharma Ireland Limited |
Thiophene compounds for long-acting injectable compositions and related methods
|
|
EP4577667A2
(en)
*
|
2022-08-25 |
2025-07-02 |
Biosynth GmbH |
Procedure for production of opioid-antagonist-releasing compounds and their use as a medicine
|